Stockreport

Genfit: Near-Term Upside Of 650% As Read-Out Of The Year Approaches [Seeking Alpha]

GENFIT S.A. - American Depositary Shares  (GNFT) 
PDF Summary NASH is a common disease with an expected market size of 20 Bn. $ in 2030 and currently no approved drugs. A handful of companies including most of big pharma ar [Read more]